• August 13, 2018
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.5 billion of senior notes, consisting of $300 million aggregate principal amount of floating rate senior notes due 2021, $300 million aggregate principal amount of 3.250% senior notes due 2021, $500 million aggregate principal amount of 3.900% senior notes due 2028 and $400 million aggregate principal amount of 4.450% senior notes due 2048, in anmore...
  • August 2, 2018
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2018 and updated its guidance for full year 2018. The company reported revenue of $1.4 billion for the second quarter of 2018, an increase of 12% compared with the second quarter of 2017. Net income for the second quarter of 2018 was $384 million, or $0.79 per diluted share, an increase of 55% and 58%, respectively, on a reported basismore...
  • July 31, 2018
    PARSIPPANY, N.J. & UNION CITY, Calif.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the completion of the acquisition of Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services for US $83 per share in cash, or approximately $2.0 billion in aggregate. The acquisition, which was first announced on May 16, follows the satisfaction of all conditions to the closing, including the receipt of the approval ofmore...
  • July 6, 2018
    PARSIPPANY, N.J. & UNION CITY, Calif.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) and Abaxis, Inc. (NASDAQ:ABAX) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Zoetis’ previously-announced acquisition of Abaxis for US $83.00 per share in cash, or approximately $2.0 billion in aggregate. The expiration of the waiting period under the HSR Act satisfies one of themore...
  • June 29, 2018
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Aug. 2, 2018. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review second quarter 2018 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://more...
  • June 6, 2018
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 2018 Growth Stock Conference on Tuesday, June 12, 2018, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 5:10 p.m. ET (4:10 p.m. CT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investormore...
  • June 6, 2018
    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Zoetis Inc. (NYSE:ZTS) today announced a five-year collaboration to research the use of Regeneron’s monoclonal antibody therapeutics in animals and discover new veterinary treatments.Under the terms of the agreement, Regeneron has granted Zoetis a license for its VelocImmune® antibody technology, which Zoetis will use to develop monoclonal antibodies modified for species-specific use in companion and livestock animals. In particular, Zoetis ismore...
  • May 22, 2018
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2018 Dental & Veterinary Conference on Wednesday, May 30, 2018, in New York, N.Y. Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, will represent the company and respond to questions from analysts. She is scheduled to present at 11:30 a.m. ET. Investors and other interested parties will be able to access a livemore...
  • May 16, 2018
    PARSIPPANY, N.J. and UNION CITY, Calif.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) and Abaxis, Inc. (NASDAQ:ABAX) today announced a definitive merger agreement pursuant to which Zoetis will acquire Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services for US $83 per share in cash, or approximately $2.0 billion in aggregate. The acquisition is expected to enhance Zoetis’ presence in veterinary diagnostics, a category of themore...
  • May 15, 2018
    PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a third quarter 2018 dividend payable to holders of the company’s common stock of $0.126 per share. The dividend is to be paid on Tuesday, Sept. 4, 2018, to holders of record on Friday, July 20, 2018. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years ofmore...